SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddy’s Laboratories informs about press release

14 Jun 2022 Evaluate

Dr. Reddy’s Laboratories enclosed a Press Release on ‘Dr. Reddy's Laboratories announces the launch of the generic version of Nexavar (sorafenib) Tablets, USP, 200 mg in the U.S. market’.

The above information is a part of company’s filings submitted to BSE.

Dr. Reddys Labs. Share Price

1376.30 26.30 (1.95%)
29-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1872.60
Dr. Reddys Labs. 1376.30
Cipla 1453.50
Zydus Lifesciences 1121.65
Lupin 2407.45
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: